Thromboprophylaxis in non-surgical patients: Who, when and how?

Haemostasis

Volumn 28, Issue SUPPL. 3, 1998, Pages 71-82

  Gallus, A S ^a   Nurmohammed, M ^b   Kearon, C ^d   Prins, M ^c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b Centre for Haemostasis and Thrombosis

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Deep vein thrombosis; Ischaemic stroke; Low molecular weight heparin; Myocardial infarction; Thromboprophylaxis

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; SPINAL CORD INJURY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOGENESIS; TREATMENT PLANNING;

AGED; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOSIS; WOUNDS AND INJURIES;

EID: 0032456424     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Palan JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
2. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A: The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992;152:1660-1664.
3. Cogo A, Bernardi E, Prandoni P, Girolami B, Noventa F, Simioni P, Giralami A: Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-168.
4. Havig O: Deep vein thrombosis and pulmonary embolism. Acta Chir Scand 1977;478(suppl):1-120.
5. Lindblad B, Sternby NH, Bergqvist D: Incidence of venous thromboembolism verified by autopsy over 30 years. BMJ 1991;302:709-711.
6. Hermann RE, Davis JH, Holden WD: A clinical and pathological study with emphasis on the effect of prophylactic therapy with anticoagulants. Am J Surg 1961;102:19-28.
7. Macintyre IMC, Ruckley CV: Pulmonary embolism - a clinical and autopsy study. Scottish Med J 1974; 19:20-24.
8. Dismuke SE, Wagner EH: Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. J Am Med Ass 1986; 255:2039-2042.
9. Mellbring G, Strand T, Eriksson S: Venous thromboembolism after cerebral infarction and the prophylactic effect of Dextran 40. Acta Med Scand 1986;220:425-429.
10. McCarthy ST, Turner J: Low-dose subcutaneous heparin in the prevention of deep vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986;15:84-88.
11. Turpie AG, Levine M, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M: Double-blind randomized trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526.
12. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH: Prophylaxis of deep vein thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989;19:245-250.
13. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U: A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Sem Thromb Hemost 1990;16(suppl):25-33.
14. Turpie AGG, Gent M, Cote R, Levine M, Ginsberg JS, Powers P, Leclere J, Geerts W, Jay R, Neemeh J, et al: A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischaemic stroke. A randomized, double-blind study. Ann Intern Med 1992;117:353-357.
15. Dumas R, Woitinas F, Kutnowski M, Nilsson P, Berberich R, Abedinpour F, Zoeckler S, Gregoire F, Jerkovic M, Egberts JF: A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep vein thrombosis in patients with acute ischaemic stroke. Age Ageing 1994;23:512-516.
16. Handley AJ, Emerson PA, Fleming PR: Heparin in the prevention of deep vein thrombosis after myocardial infarction. BMJ 1972;2:436-438.
17. Warlow C. Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS: A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973;2:934-936.
18. Emerson PA, Marks P: Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. BMJ 1977;1:18-20.
19. Handley AJ: Low-dose heparin after myocardial infarction. Lancet 1972; 2:623-624.
20. Wray R, Maurer B, Shillingford J: Prophylactic anticoagulant therapy in the prevention of calf-vein thrombosis after myocardial infarction. New Engl J Med 1973;288:815-817.
21. Pitney WR, Pussell BA, Harris M, Manohar D: The subcutaneous use of heparin in the prevention of venous thrombosis after myocardial infarction. Med J Australia 1974;1: 38-40.
22. Pitt A, Anderson ST, Habersberger PG, Rosengarten DS: Low dose heparin in the prevention of deep-vein thrombosies in patients with acute myocardial infarction. Am Heart J 1980;99:574-578.
23. Belch JJ, Lowe GDO, Ward AG, Forbers CD, Prentice CRM: Prevention of deep-vein thrombosis in medical patients by low-dose heparin. Scottish Med J 1981;26:115-117.
24. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM: Prevention of deep vein thrombosis in elderly medical inpatients by a low-molecular-weight heparin: a randomized double-blind trial. Haemostasis 1986;16:159-164.
25. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, Arevila-Ceballos N, Fong JH, Sanchez-Martinez R, et al: Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988;39:505-513.
26. Bergmann J-F, Neuhart E: A multicentre randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-534.
27. Wade WE: Cost-effectiveness of venous thrombosis prophylaxis following ischaemic stroke: an assessment of currently available literature. Thromb Res 1998;89:199-202.
28. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
29. Cairns JA, Lewis HDJr, Meade TW, Sutton GC, Theroux P: Antithrombotic agents in coronary artery disease. Chest 1995;108(suppl):380-400.
30. Kierkegaard A, Norgren L: Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. Eur Heart J 1993;14:1365-1368.
31. Harenberg J, Roebruck P, Heene DL: Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical patients. Haemostasis 1996;26:127-139.
32. Lechler E, Schramm W, Flosbach CW, THE PRIME Study Group: The venous thrombotic risk in nonsurgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996;26 (suppl):49-56.
33. Halkin H, Goldberg J, Modan B: Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-565.
34. Caulin C: The influence of CY216 administration on hospital mortality of general medical inpatients. International collaborative double-blind study: methods and preliminary results; in Breddin K, Fareed J, Samama M (eds): Fraxiparine. First international symposium. Analytical and structural data, pharmacology, clinical trials. New York, Schattauer, 1989, pp 147-152.
35. Gardlund B, and the Heparin Prophylaxis Study Group: Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious disease. Lancet 1996;347: 1357-1361.
36. Lederle FA: Heparin prophylaxis for medical patients? Ann Intern Med 1998;128:768-770.
37. Waring WP, Karunas RS: Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease. Paraplegia 1991;29:8-16.
38. Green D, Lee MY, Lim AC, Chmiel JS, Vetter M, Pang T, Chen D, Fenton L, Yarkony GM, Meyer PR Jr: Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990;113:571-574.
39. Green D, Lee MY, Ito VY, Cohn T, Press J, Filbrandt PR, Vandenberg WC, Yarkony GM, Meyer PR Jr: Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. J Am Med Ass 1988;260:1255-1258.
40. Harris S, Chen D, Green D: Enoxaparin for thromboembolism prophylaxis in spinal injury. Am J Phys Med Rehab 1996;75:326-327.
41. Silver JR: The prophylactic use of anticoagulant therapy in the prevention of pulmonary emboli in one-hundred consecutive spinal injury patients. Paraplegia 1974;12: 188-196.
42. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP: A prospective study of venous thromboembolism after major trauma. New Engl J Med 1994;331:1601-1606.
43. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibibil EA, Hamilton PA: A comparison of lowdose heparin with low-molecular-weight heaprin as prophylaxis against venous thromboembolism after major trauma. New Engl J Med 1996;335:701-707.
44. Brasel KJ, Borgstrom DC, Weigelt JA: Cost-effective prevention of pulmonary embolus in high-risk trauma patients. J Trauma 1997;42: 456-460.
45. Napolitano LM, Garlapati VS, Heard SO, Cutler BS, O'Neill AM, Anderson FA, Silva WA, Wheeler HB: Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol justified? J Trauma 1995;39:651-657.
46. Meyer CS, Blebea J, Davis KJr, Fowl RJ, Kempczinski RF: Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg 1995;9:109-114.
47. Satiani B, Falcone R, Shook L, Price J: Screening for major deep vein thrombosis in seriously injured patients: a prospective study. Ann Vasc Surg 1997;11:626-629.
48. Spain DA, Richardson JD, Polk HCJr, Bergamini TM, Wilson MA, Miller FB: Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma 1997; 42:463-469.
49. Neuhaus A, Bentz RR, Weg JG: Pulmonary embolism in respiratory failure. Chest 1978;73:460-465.
50. Ryskamp RP, Trottier SJ: Utilization of venous thromboembolism prophylaxis in a medical-surgical ICU. Chest 1998;113:162-164.
51. Hirsch DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. J Am Med Ass 1995;274:335-337.
52. Marik PE, Andrews L, Maini B: The incidence of deep venous thrombosis in ICU patients. Chest 1997;111: 661-664.
53. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348: 423-428.
54. Landefeld S, Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-328.
55. Hirsh J, Kearon C, Ginsberg J: Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157: 2174-2177.
56. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Ass 1998;279:458-462.
57. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg J: The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991;66: 520-524.
58. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH: Anticardioloipin antibodies and the risk for ischaemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
59. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE: A prospective study of risk factors for pulmonary embolism in women. J Am Med Ass 1997; 277:642-645.
60. van den Belt AGM, Sanson B-J, Simioni P, Prandoni P, Buller HR, Girolami A, Prins MH: Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997;157:2227-2232.
61. Ezekowitz M: Antithrombotics for left-ventricular impairment? Lancet 1998;351:1904-1905.
62. Antiplatelet Triallists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308:235-246.
63. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF: Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112:423-428.
64. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D: Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer [comment]. Lancet 1994;343:886-889.
65. Kearon C, the LAFIT Investigators: Two years of warfarin versus placebo following three months of anticoagulation for a first episode of venous thromboembolism (abstract). Thromb Haemost 1997(suppl):767.
66. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New Engl J Med 1997;336:393-398.
67. Levine MN, Raskob G, Landefeld S, Hirsh J: Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(suppl):276-290.
68. Volksegczondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010; Ruwaard D, Kramers PGN. SDU The Hague, 1993.
69. Morgenthaler TI, Ryu JH: Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clinic Proceed 1995;70:417-424.
70. Shen VS, Pollak EW: Fatal pulmonary embolism in cancer patients. is heparin prophylaxis justified? Southern Med J 1980;73:841-843.
71. Nielsen HK, Bechgaard P, Nielsen PF, Husted SE, Geday E: 178 fatal cases of pulmonary embolism in a medical department. Acta Med Scand 1981;209:351-355.